Incyte
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 2.5K
- Market Cap
- $12.6B
- Introduction
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
Not Applicable
Not yet recruiting
- Conditions
- Hidradenitis Suppurativa
- First Posted Date
- 2025-07-03
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 24
- Registration Number
- NCT07049575
Study to Assess the Safety, Tolerability, and Pharmacokinetics of INCB000631 When Administered Orally to Healthy Adult Participants
- First Posted Date
- 2025-06-26
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 48
- Registration Number
- NCT07039929
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- First Posted Date
- 2025-06-17
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 160
- Registration Number
- NCT07023627
A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants
Phase 1
Not yet recruiting
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2025-06-12
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 72
- Registration Number
- NCT07018635
A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
Phase 1
Not yet recruiting
- Conditions
- Myeloproliferative Neoplasms
- Interventions
- Drug: INCA035784
- First Posted Date
- 2025-06-06
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 120
- Registration Number
- NCT07008118
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)
Phase 3
Recruiting
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Drug: Vehicle Cream
- First Posted Date
- 2025-05-06
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 400
- Registration Number
- NCT06959225
- Locations
- 🇺🇸
Investigative Site US019, Marietta, Georgia, United States
🇺🇸Investigative Site US026, Chicago, Illinois, United States
🇺🇸Investigative Site US042, Libertyville, Illinois, United States
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
Phase 3
Recruiting
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Drug: Vehicle Cream
- First Posted Date
- 2025-05-06
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 450
- Registration Number
- NCT06958211
- Locations
- 🇺🇸
Investigative Site US271, Wildwood, Missouri, United States
🇺🇸Investigative Site US257, Birmingham, Alabama, United States
🇺🇸Investigative Site US218, Birmingham, Alabama, United States
A Study to Evaluate the Relative Bioavailability of New Formulations of INCB057643 Tablets Administered Orally in Healthy Participants
- First Posted Date
- 2025-04-23
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 48
- Registration Number
- NCT06941077
- Locations
- 🇺🇸
Celerion, Inc, Tempe, Arizona, United States
A Study to Evaluate Microneedle-based Collection of Dermal Interstitial Skin Fluid in Healthy Participants and Atopic Dermatitis Participants
Not yet recruiting
- Conditions
- Atopic DermatitisHealthy Volunteers
- First Posted Date
- 2025-04-18
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 20
- Registration Number
- NCT06934980
An Early Access Program Guideline to Provide Access to Retifanlimab (INCMGA00012) Together With Carboplatin and Paclitaxel for Squamous Carcinoma of the Anal Canal (SCAC)
- Conditions
- Squamous Cell Carcinoma of the Anal Canal
- First Posted Date
- 2025-04-04
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Incyte Corporation
- Registration Number
- NCT06910137